Innovair Nexthaler

Formoterol fumarate and beclometasone dipropionate, the active ingredients in Innovair Nexthaler, are a LABA/ICS combination presented as an inhalation powder for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adults and adolescents who require regular control of airway inflammation and bronchodilation, typically administered once or twice daily to maintain stable lung function.

GNH USA supplies Innovair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Innovair Nexthaler is a LABA/ICS inhaler used in the management of chronic airway diseases.

- Asthma: improves long‑term symptom control and reduces exacerbation frequency in patients requiring maintenance therapy. - Chronic obstructive pulmonary disease (COPD): helps maintain lung function and decreases the rate of COPD flare‑ups in adult patients. - Asthma‑COPD overlap (ACO): provides combined bronchodilation and anti‑inflammatory effects to improve overall respiratory stability.

The most frequently reported adverse reactions with Innovair Nexthaler involve the respiratory tract and systemic effects of the inhaled corticosteroid.

Common Side Effects: - Throat irritation or soreness - Hoarseness or voice change - Oral candidiasis (thrush) - Cough - Headache - Tremor

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Adrenal suppression with long‑term high‑dose use - Pneumonia, particularly in COPD patients - Cardiac arrhythmias or tachycardia - Hyperglycaemia in susceptible individuals

When prescribing Innovair Nexthaler, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess asthma or COPD control before initiating: confirm that the patient remains symptomatic despite low‑dose inhaled corticosteroid therapy. - Monitor for oral candidiasis: advise patients to rinse mouth and clean the device after each use. - Avoid abrupt discontinuation: sudden withdrawal may lead to loss of bronchodilation and symptom worsening. - Use the lowest effective dose: to minimise systemic exposure to corticosteroid. - Store at ambient temperature: keep the inhaler in its original packaging, protect from moisture and excessive heat.

Innovair Nexthaler may interact with other medicines, affecting either its bronchodilator component or corticosteroid component.

Major Interactions (Avoid): - Non‑selective beta‑blockers: can diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): may increase cardiovascular side effects of formoterol. - Diuretics or other agents that lower serum potassium: risk of hypokalaemia when combined with β2‑agonists.

Moderate Interactions (Monitor Closely): - Concomitant inhaled corticosteroids: increase risk of systemic corticosteroid effects. - Strong CYP3A4 inhibitors (e.g., ritonavir): may raise formoterol plasma levels. - Theophylline: combined use can enhance risk of tachyarrhythmias.